Rules-Based Medicine

(+01) 512 835 8026

Email us

Type your search term and press "enter."



Interferon gamma (IFN-gamma)

Ultrasensitive Immunoassay


Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to interferon gamma (IFN-γ) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of IFN-γ in serum or plasma. The assay can assist in clinical studies with various indications including monitoring immune activity in response to cancer vaccines and the diagnosis of tuberculosis.

IFN-γ is the sole member of the type II interferon family and is critical for both innate and adaptive immunity. IFN-γ has a distinct structure and function as well as a more restricted expression pattern compared to its type I family members. The mature form of IFN-γ is a glycosylated, noncovalent homodimer produced and secreted by activated lymphocytes. IFN-γ binds to the IFN-γR1 receptor subunit which engages the IFN-γR2 receptor subunit to activate JAK1 and JAK2. The pleiotropic effects of IFN-γ are mediated through the expression of hundreds of IFN-γ-regulated genes including inflammatory signaling molecules, apoptotic regulators, and other transcription factors.

The role of IFN-γ in the activation of the immune response has led to its use in various clinical applications including fungal diseases as well as certain types of cancers and autoimmune diseases. Recombinant IFN-γ has been approved by the FDA to reduce the severity of infections associated with Chronic Granulomatous Disease (CGD) and for the treatment of severe, malignant osteopetrosis. Additionally, IFN-γ is crucial for tumor surveillance by the immune system and also has direct anti-tumor effects in some types of cancers. Elevated levels of IFN-γ play an essential role in the development and severity of some autoimmune diseases which has led to the generation and testing of monoclonal antibodies to neutralize the effects of IFN-γ in diseases such as Crohn’s diseases, rheumatoid arthritis, and systemic lupus erythematosus.


Swiss-Prot Accession Number: P01579

Simoa™ Services
Biomarker LLOQ*
(Serum and Plasma)
(Undiluted Samples)
Volume Required
Serum or plasma Other fluids**
Interferon gamma (IFN-gamma) 0.019 pg/mL 0.0095 pg/mL 150 µL 150 µL

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.